Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkEffect of Celecoxib vs. Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients with Breast Cancer

Is there a benefit for patients who receive celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)–negative primary breast cancer? A report on the Randomized European Celecoxib Trial (REACT), a phase 3, randomized, double-blind study conducted in 160 centers across the UK and Germany testing two years of adjuvant celecoxib vs. placebo among 2,639 patients recruited between 2007 and 2012, with follow-up 10 years after treatment completion.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form